ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 167,50
-0,26%
Dow Jones
40 003,59
0,34%
DAX
18 704,42
-0,11%
Brent Oil
83,76
0,67%
Bitcoin
66 935,70
2,60%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. ZyVersa Therapeutics Inc (ZVSA)

  7. ZyVersa Therapeutics Inc (ZVSA) Actualités

ZVSA

ZyVersa Therapeutics (ZVSA)

ZyVersa Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:ZVSA
DateHeureSourceTitreSymboleSociété
15/05/202414h35GlobeNewswire Inc.ZyVersa Therapeutics Reports First Quarter, 2024 Financial Results and Provides Business UpdateNASDAQ:ZVSAZyVersa Therapeutics Inc
15/05/202414h30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ZVSAZyVersa Therapeutics Inc
15/05/202414h25Edgar (US Regulatory)Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]NASDAQ:ZVSAZyVersa Therapeutics Inc
14/05/202413h57GlobeNewswire Inc.ZyVersa Therapeutics' CEO, Stephen C. Glover, to Participate in the 2024 BIO International ConventionNASDAQ:ZVSAZyVersa Therapeutics Inc
29/04/202413h57GlobeNewswire Inc.ZyVersa Therapeutics Announces Publication Reinforcing the Rationale for Inhibiting ASC with IC 100 to Potentially Attenuate Cardiac Comorbidities in Patients with Alzheimer’s DiseaseNASDAQ:ZVSAZyVersa Therapeutics Inc
04/04/202413h57GlobeNewswire Inc.ZyVersa Therapeutics Highlights Published Data Demonstrating NLRP3 Inflammasome Inhibition Has Potential to Decrease Atherosclerotic Lesions in Patients with DiabetesNASDAQ:ZVSAZyVersa Therapeutics Inc
25/03/202413h17GlobeNewswire Inc.ZyVersa Therapeutics Reports Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:ZVSAZyVersa Therapeutics Inc
18/03/202412h57GlobeNewswire Inc.ZyVersa Therapeutics Announces IRB Approval of Phase 2a Clinical Trial Protocol to Evaluate Cholesterol Efflux Mediator™ VAR 200 in Patients with Diabetic Kidney DiseaseNASDAQ:ZVSAZyVersa Therapeutics Inc
14/03/202412h57GlobeNewswire Inc.ZyVersa Therapeutics' CEO, Stephen C. Glover to Participate in a Panel Discussion Titled “Inflammation Illuminated,”at Benzinga’s Virtual Healthcare Summit 2024 on March 20, 2024NASDAQ:ZVSAZyVersa Therapeutics Inc
08/03/202423h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ZVSAZyVersa Therapeutics Inc
08/03/202423h00Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:ZVSAZyVersa Therapeutics Inc
29/02/202413h57GlobeNewswire Inc.ZyVersa Therapeutics Generated Approximately $2.7 Million From Exercise of Warrants Following Excitement Around News That Inflammasome Inhibitors Have Potential to Effectively Treat ObesityNASDAQ:ZVSAZyVersa Therapeutics Inc
28/02/202413h57GlobeNewswire Inc.ZyVersa Therapeutics Highlights Data from Review Article Published in Nature Reinforcing IC 100’s Rationale for Inhibiting ASC and ASC Specks to Attenuate Damaging Inflammation Associated with Various Conditions, Including Obesity and Its ComplicationsNASDAQ:ZVSAZyVersa Therapeutics Inc
22/02/202413h47GlobeNewswire Inc.ZyVersa Therapeutics Publishes New White Paper Detailing the Role of Inflammasomes and ASC Specks in Neurological Diseases, and Data Supporting Inflammasome ASC Inhibitor IC 100 as a Potential Therapeutic OptionNASDAQ:ZVSAZyVersa Therapeutics Inc
14/02/202422h34Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ZVSAZyVersa Therapeutics Inc
14/02/202413h53GlobeNewswire Inc.ZyVersa Therapeutics Highlights Review Article Substantiating That Inflammasome Activation Is Pathogenic in Multiple Neurological DiseasesNASDAQ:ZVSAZyVersa Therapeutics Inc
07/02/202414h02GlobeNewswire Inc.ZyVersa Therapeutics' CEO, Stephen C. Glover to Present at the 2024 BIO CEO & Investor Conference to Provide Corporate Update and Discuss Key MilestonesNASDAQ:ZVSAZyVersa Therapeutics Inc
31/01/202413h57GlobeNewswire Inc.ZyVersa Therapeutics Highlights Publication Indicating That Inflammasome NLRP3-Mediated Inflammation in Obese Children Leads to Insulin Resistance and Risk of Complications Such as Type 2 DiabetesNASDAQ:ZVSAZyVersa Therapeutics Inc
24/01/202413h57GlobeNewswire Inc.ZyVersa Therapeutics Announces Peer-Reviewed Article Supporting the Therapeutic Potential of Targeting ASC Specks During Progression of Alzheimer’s DiseaseNASDAQ:ZVSAZyVersa Therapeutics Inc
19/01/202412h19Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ZVSAZyVersa Therapeutics Inc
17/01/202413h52GlobeNewswire Inc.ZyVersa Therapeutics Highlights Peer-Reviewed Article Linking Inflammasome Activation to Triple-Negative Breast Cancer Brain MetastasisNASDAQ:ZVSAZyVersa Therapeutics Inc
10/01/202414h06GlobeNewswire Inc.ZyVersa Therapeutics’ CEO, Stephen C. Glover, Featured on Benzinga All AccessNASDAQ:ZVSAZyVersa Therapeutics Inc
04/01/202413h50GlobeNewswire Inc.ZyVersa Therapeutics Announces Equity Research Coverage Initiated by Noble Capital MarketsNASDAQ:ZVSAZyVersa Therapeutics Inc
03/01/202414h07GlobeNewswire Inc.ZyVersa Therapeutics CEO, Stephen C. Glover, Issues Letter to Shareholders Providing Outlook for 2024NASDAQ:ZVSAZyVersa Therapeutics Inc
18/12/202314h12GlobeNewswire Inc.ZyVersa Therapeutics’ CEO, Stephen C. Glover, to Participate in BIO Partnering @ JPM During “J.P. Morgan Week 2024”NASDAQ:ZVSAZyVersa Therapeutics Inc
14/12/202313h01GlobeNewswire Inc.ZyVersa Therapeutics Engages CRO, George Clinical, for Phase 2a Clinical Trial for Cholesterol Efflux Mediator VAR 200NASDAQ:ZVSAZyVersa Therapeutics Inc
08/12/202322h44Edgar (US Regulatory)Form 424B4 - Prospectus [Rule 424(b)(4)]NASDAQ:ZVSAZyVersa Therapeutics Inc
07/12/202317h20GlobeNewswire Inc.ZyVersa Therapeutics Announces Publication Demonstrating That Plasma Levels of NLRP3 Inflammasomes Correlate with Progression of Diabetic Kidney Disease in Patients with Type 2 DiabetesNASDAQ:ZVSAZyVersa Therapeutics Inc
07/12/202306h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ZVSAZyVersa Therapeutics Inc
07/12/202303h00GlobeNewswire Inc.ZyVersa Therapeutics, Inc. Announces Pricing of $5.0 Million Public OfferingNASDAQ:ZVSAZyVersa Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:ZVSA

Dernières Valeurs Consultées

LSE
FDN
Ft Fdn
COIN
SSSSUSD
EU
PX1GR
CAC 40 Gross TR
BIT
X42123
Natixis
LSE
40CM
Arab Rep.egp 30
BIT
UIK746
Unicredit Bank
KUCN
CMPUSDT
Caduceus
LSE
MMM
Mining Minerals & Metals
GATE
DOGAUSDT
Dogami
XE
XS4
ON Semiconductor
TSX
NINT
NBI Active International...
LSE
SLE
San Leon Energy
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés